

Acta Haematologica

Acta Haematol , DOI: 10.1159/000531128

Received: February 7, 2023

Accepted: May 15, 2023

Published online: May 19, 2023

The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of an inverted 55 base pair ABL1 intron 1b sequence: a detailed molecular analysis

Burmeister T, Bullinger L, le Coutre P

ISSN: 0001-5792 (Print), eISSN: 1421-9662 (Online)

<https://www.karger.com/AHA>

Acta Haematologica

Disclaimer:

Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:

This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY) (<http://www.karger.com/Services/OpenAccessLicense>). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.

© 2023 The Author(s). Published by S. Karger AG, Basel

Case Report

The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of an inverted 55 base pair ABL1 intron 1b sequence: a detailed molecular analysis

Thomas Burmeister^{a,b}, Lars Bullinger^a, Philipp le Coutre^c

^a Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow, Medizinische Klinik für Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany

^b Labor Berlin Charité – Vivantes, 13353 Berlin, Germany

^c Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Mitte, Medizinische Klinik für Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany

Short title: e8a2 BCR::ABL1 with 55 base pair ABL1 intron 1b insertion

Corresponding Author:

Thomas Burmeister

Medizinische Klinik für Hämatologie, Onkologie und Tumorimmunologie, Campus Virchow
Charité – Universitätsmedizin Berlin

Augustenburger Platz 1

13353 Berlin, Germany

Tel: +49 (0)30450653154

E-mail: thomas.burmeister@charite.de

Number of Tables: 0

Number of Figures: 3

Word count: abstract 144 words, body text: 1864 words

Keywords: BCR::ABL1, chromosomal translocation, atypical transcript, cryptic exon

Abstract

Atypical *BCR::ABL1* transcripts are found in approximately 2% of cases of chronic myeloid leukemia. It is important to detect them, since affected patients also benefit from tyrosine kinase inhibitor therapy. In the rare e8a2 atypical *BCR::ABL1* transcript two out-of-frame exons are fused, thus, interposed nucleotides are usually found at the fusion site to restore the reading frame. In approximately half of previously reported e8a2 *BCR::ABL1* cases an inserted 55 bp sequence homologous to an inverted sequence from *ABL1* intron 1b was detected. The generation of this recurrent transcript variant is not obvious. This work describes the molecular analysis of such an e8a2 *BCR::ABL1* translocation from a CML patient. The genomic chromosomal breakpoint is identified, and the formation of this transcript is theoretically explained. The clinical course of the patient is reported, and recommendations are provided for the molecular analysis of future e8a2 *BCR::ABL1* cases.

Accepted Manuscript

Introduction

The chimeric *BCR::ABL1* gene is the molecular hallmark of chronic myeloid leukemia (CML). More than 95% of *BCR::ABL1*-positive CML patients reveal a *BCR::ABL1* transcript showing a fusion of either *BCR* exon 13 or 14 and *ABL1* exon 2 (transcripts e13a2 and e14a2), indicating a chromosomal breakpoint in the so-called "major breakpoint cluster region" in *BCR*. Other "atypical" *BCR::ABL1* transcripts with different exon fusions are rarely found. One of these is the e8a2 *BCR::ABL1* transcript, first described by How et al. (1999) and Branford et al. (2000), [1, 2] of which only a handful of cases have been reported. The generation of this transcript type is more complex since *BCR* exon 8 and *ABL1* exon 2 are not in the same reading frame, thus, a simple fusion of the two exons should not lead to a functional *BCR::ABL1* oncoprotein. In fact, the large majority of previously described e8a2 *BCR::ABL1* transcripts showed an insertion of additional nucleotides that were derived from intronic sequences of *ABL1*, *BCR* or other genes, with only very few (difficult to explain) exceptions. [3, 4] Approximately half of the previously reported e8a2 *BCR::ABL1* transcript cases showed a 55 base pair (bp) insertion matching an inverted sequence from *ABL1* intron 1b. [2, 5–7] How this intronic inverted sequence is incorporated into the final chimeric mRNA transcript is not obvious and has not been investigated previously.

We describe the case of a patient with CML and an e8a2 *BCR::ABL1* transcript with such an inverted interposed sequence. We molecularly identified the chromosomal breakpoint and provide a theoretical explanation for the generation of this transcript variant. Implications for molecular monitoring are discussed.

Case Presentation

Patient's history

The patient, a 74-year-old male from Germany presented with a myeloproliferative neoplasm. He presented with a leukocyte count of $110 \times 10^9/L$, hemoglobin 15.6 g/dl and $178 \times 10^9/L$ platelets. The differential blood count showed 5% lymphocytes, 2% eosinophils, 3% basophils, 8% neutrophilic band forms, 57% segmented neutrophils, 10% metamyelocytes, 7% myelocytes, 5% promyelocytes, and 3% blasts. Clinically he was largely asymptomatic. While the karyotype 46,XY,t(9;22)(q34;q11.2) [3] suggested a Philadelphia translocation the initial RT–PCR analysis in an external laboratory failed to detect a *BCR::ABL1* transcript. RT–PCR analysis by multiplex PCR in our laboratory and subsequent sequencing of the PCR product revealed an e8a2 *BCR::ABL1* transcript with the aforementioned 55 bp insertion. [8] Bone marrow histology showed a myeloproliferative neoplasm with less than 2% blasts and a focal discrete fibrosis. The patient first received hydroxyurea for a few days and then 2×300 mg nilotinib daily. Molecular analysis by RT–qPCR using a quantitative PCR method with a newly designed primer in *BCR* exon 8 together with the standardized EAC cycling conditions and *ABL1* as a housekeeping gene [9, 10] showed a reduction in the relative *BCR::ABL1* level to a value of 10^{-3} in the peripheral blood after twelve months of therapy (Fig. 1).

Genetic analysis of the *BCR::ABL1* break region

The procedures of the genetic analysis are illustrated in Figure 2. Technical details such as PCR methods and primer sequences are provided in the online supplement to this report. All nucleotide positions refer to the human genome assembly GRCh38.p14 139608 bp *ABL1* intron 1 (NC_000009.12:130714456-130854063) and 10202 bp *BCR* intron 8 (NC_000022.11:23273775-23283976). After sequencing the mRNA transcript (Fig. 2a) all further molecular analyses were performed with genomic DNA. The break on chromosome 22 was assumed to be in the 10.2 kb *BCR* intron 8. Since the inverted intronic sequence was located near *ABL1* exon 1b (Fig. 2b), we hypothesized that one *ABL1* break occurred near the 5' end of *ABL1* intron 1b. Long-range PCRs with different PCR primers located in the inverted sequence and in various parts of *BCR* exon/intron 8 were performed which resulted in the identification of the 5' break in *BCR* intron 8 at nt 7894 and in *ABL1* intron 1b at nt 1072 (Fig. 2c). To obtain an estimate of the location of the second (3') break, i.e., the size of the inverted segment, various long-range PCRs were performed with one primer located in *BCR* intron 8 immediately 5' of the breakpoint and the second primer in (inverted) *ABL1* at various

distances 3' to the inverted fragment. This revealed that a second break was located still in *ABL1* intron 1b and not further 5' upstream.

This 3' break in *ABL1* intron 1b was identified using a long-range inverse PCR approach with one primer located in the inverted fragment and the other in *BCR* intron 8 as shown in Fig. 2c. Three different restriction enzymes were tested and the enzyme *TaqI* led to the identification of the 3' break in *ABL1* intron 1b (Fig. 2c).

The 3' break in *ABL1* was located at nt 1415 of intron 1b. An 878 bp sequence fragment spanning from nt 195 to nt 1072 with 100% sequence identity to the *ABL1* reference sequence was inserted in reverse complement, while 342 bp of DNA sequence between nt 1073 and 1414 of *ABL1* intron 1b were missing (Fig. 3a).

Genetic analysis of the *ABL1::BCR* breakpoint region

No expression of a chimeric *ABL1::BCR* transcript was detected by RT-PCR using PCR primers located in *ABL1* exon 1b and *BCR* exon 9.

Bioinformatic analysis of the breakpoint region

The complete breakpoint region in *ABL1* and *BCR* was sequenced from a remission sample of the patient to analyze possible sequence variations that could have facilitated the chromosomal break event. Genomic repeats were analyzed with *RepeatMasker* version 4.0.9, *RSSsite* and the *Tandem repeats finder*. [11–13] No repetitive element was identified in the vicinity of the breakpoint in *BCR* while four elements were identified in the first 1500 bp of *ABL1* intron 1b (elements with intronic location: MIR3 218–322 bp, Charlie4z 400–452 bp, L1ME3G 1226–1333 bp, Charlie1a 1345–1501 bp). No tandem repeats or microhomologies were detected at the break sites. There was one potential 12 bp cryptic recombination signal sequence (cRSS) at 279–306 bp and two potential 23 bp cRSSs at 385–423 bp and at 1242–1280 bp. All three cRSSs were on the (-) strand. No single nucleotide polymorphisms were detected.

Discussion

Various e8a2 *BCR::ABL1* transcript variants have been reported in the literature. Many of them were singular cases showing interposed short nucleotide sequences derived from different chromosomes and genes. [14–16] The 55 bp *ABL1* insert e8a2 *BCR::ABL1* variant is of particular theoretical interest since it has been recurrently observed. None of the previously reported e8a2 *BCR::ABL1* cases was analyzed on the genomic level.

Genetic analysis

Previous work has located *BCR::ABL1* chromosomal breaks in the first 1.5 kb of *ABL1* intron 1b. Linhartova et al. analyzed the der(22) chromosomal breaks of CML patients with e13a2/e14a2 transcripts. [17] Three of the analyzed 46 breaks in *ABL1* intron 1b were located in this region (with GenBank accession numbers): at nt 866 (KR092020), nt 841 (KR091994), and nt 604 (KR092015). Krumbholz et al. identified the der(22) and/or der(9) break locations in 59 pediatric CML patients. [18] Six of them mapped to the break region at 575 bp (JQ425201), 698 bp (JQ425193), 1154 bp (JQ425167), 1276 bp (JQ425228), 1280 bp (JQ425229), and 1435 bp (JQ425168). In the author's previous work however, none of the 64 identified der(22) and der(9) chromosomal breaks of e13a2/e14a2-*BCR::ABL1*-positive patients were located in this region. [19] Thus there was a higher density of *BCR::ABL1* break events in this region than could statistically be expected. When analyzing the breakpoint junctions in the current case no microhomologies, repetitive DNA elements or cryptic recombination signal sequence (RSS) sites were found that were likely involved in the chromosomal break. The question of whether those elements play a role in the formation of the *BCR::ABL1* translocation has been controversially discussed. [17–22]

A reciprocal der(9) or *ABL1::BCR* fusion breakpoint could not be characterized. Since no expression of an *ABL1::BCR* mRNA transcript was detectable by RT-PCR, it is possible that the translocation led to a partial or complete deletion of the reciprocal allele. Such deletions of der(9) are frequently observed

in CML[23] and the abovementioned studies also did not detect reciprocal *ABL1::BCR* breakpoints in a significant percentage of cases.

Activation of a cryptic exon

The incorporation of the 55 bp sequence between *BCR* exon 8 and *ABL1* exon 2 in the detected mRNA transcript can be theoretically explained by the activation of a cryptic exon (Fig. 3). This has already been hypothesized by Tchirkov et al. (2006) but the authors did not investigate it on the genomic level.[24] The 55 bp cryptic exon possessed intact splice donor and splice acceptor sites, a small polypyrimidine tract and putative splice branching site, which however did not fully match the consensus YNYTRAY motif.[25] Whether this cryptic exon was activated by some kind of abnormality or variant in the splicing apparatus of our patient remains unclear, since there is no known transcriptional unit on the minus strand of the *ABL1* gene locus, thus, it cannot be decided if this exon is spliced in healthy individuals. As can be seen from the sequence chromatogram in Fig. 2a, a transcript with direct fusion of *BCR* exon 8 and *ABL1* exon 2 is also transcribed with low efficiency, but this should not result in a functional *BCR::ABL1* protein.

The cryptic exon was also predicted with some probability by bioinformatic web-based tools, albeit with only moderate probability: NetGene2-2.42 ($p=0.83$ donor, $p=0.77$ acceptor splice site)[26] and GENSCAN ($p=0.304$).[27]

Molecular monitoring

Molecular monitoring of atypical *BCR::ABL1* transcripts poses a diagnostic problem, since no international guidelines exist for this process. In the case of the typical e13a2/e14a2 *BCR::ABL1* transcripts the EAC PCR primers are widely used, and detailed recommendations for molecular monitoring have been issued,[28] but no such guidelines exist for atypical transcripts. Recently, Schäfer et al. (2021) addressed this problem and designed and tested PCR primers for several atypical *BCR::ABL1* transcripts, including e8a2, using a relative patient-specific scale, i.e., the *BCR::ABL1* transcript level at diagnosis was set to 100% and the relative reduction was calculated during the time course.[29] We adopted this approach, albeit with different PCR primers and probe and our patient showed a significant reduction in the relative *BCR::ABL1* level to about below 10^{-3} (0.1%) after nine months of therapy.

Conclusions

This report investigated and elucidated the molecular background of the recurrent e8a2 *BCR::ABL1* transcript variant with an interposed 55 bp inverted *ABL1* sequence. The generation of this *BCR::ABL1* variant is explained by a complex chromosomal translocation involving three chromosomal breaks with partial inversion of and deletion in the *ABL1* gene locus and subsequent activation of a cryptic exon on the minus DNA strand. Although this transcript variant is recurrent, i.e., repeatedly experimentally observed, it does not imply that the underlying chromosomal break events are identical in different 55 bp insert e8a2 *BCR::ABL1* cases. To obtain a better understanding of the generation of this variant we suggest the molecular investigation of future e8a2 cases also at the genomic level. The steps undertaken in our work could serve as a model for such an analysis.

Statements

Acknowledgement

The authors wish to thank Ms. Daniela Gröger for her skillful technical work and Ms. Thekla Schwarzer for organizational assistance.

Statement of Ethics

Our research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. This retrospective review of patient data did not require ethical approval in accordance with local and national guidelines.

Conflict of Interest Statement

TB received speakers' honoraria from Novartis and Pfizer. LB received honoraria from Sanofi, Astellas, Amgen, consultancy fee from Gilead, Hexal, and Menarini, consultancy fee and honoraria from Abbvie, BMS/Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis and Pfizer, and research funding from Bayer and Jazz Pharmaceuticals. PC received speakers' honoraria from Novartis, BMS, Incyte and Pfizer.

Funding Sources

The work was funded by institutional research support.

Author Contributions

TB designed research and drafted the manuscript. LB and PC treated the patient and contributed to the manuscript. All authors read and approved the final manuscript.

Data Availability Statement

The nucleotide sequence of the chromosomal break sequence has been submitted to the GenBank/EMBL/DDBJ database and is available under accession number OP797408. Further enquiries can be directed to the corresponding author.

References

1. How GF, Lim LC, Kulkarni S, Tan LT, Tan P, Cross NC. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. *Br J Haematol.* 1999;105:434-436.
2. Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. *Br J Haematol.* 2000;109:635-637.
3. Jin C, Zhu X, Xiao M, Liu S, Liu X, Liu J et al. A Novel e8a2 BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia. *Ann Lab Med.* 2018;38:169-171.
4. Mroczkowska A, Jaźwiec B, Urbańska-Rakus J, Szymanowska S, Tessmann A, Pająk S et al. A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript. *BMC Med Genomics.* 2022;15:20.
5. Sugimoto T, Ijima K, Hisatomi H, Murayama T, Mizuno I, Hato A et al. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence. *Am J Hematol.* 2004;77:164-166.
6. Cayuela JM, Rousselot P, Nicolini F, Espinouse D, Ollagnier C, Bui-Thi MH et al. Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. *Leukemia.* 2005;19:2334-2336.
7. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T et al. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants. *Leukemia.* 2005;19:681-684.
8. Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. *Leuk Res.* 2008;32:579-585.
9. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. *Leukemia.* 2003;17:2318-2357.
10. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. *Leukemia.* 2003;7:2474-2486.
11. Tempel S. Using and understanding RepeatMasker. *Methods Mol Biol.* 2012;859:29-51.
12. Merelli I, Guffanti A, Fabbri M, Cocito A, Furia L, Grazini U et al. RSSsite: a reference database and prediction tool for the identification of cryptic Recombination Signal Sequences in human and murine genomes. *Nucleic Acids Res.* 2010;38:W262-7.
13. Benson G. Tandem repeats finder: a program to analyze DNA sequences. *Nucleic Acids Res.* 1999;27:573-580.
14. Huet S, Dulucq S, Chauveau A, Ménard A, Chomel JC, Maisonneuve H et al. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts. *Genes Chromosomes Cancer.* 2015;54:595-605.
15. Riva E, Manrique Arechavaleta G, De Almeida C, Costa V, Fernandez Del Campo M, Ifran González S et al. A novel e8a2 BCR-ABL1 fusion with insertion of MAST2 exon 2 in a four-way translocation t(1;17;9;22)(p35;q24;q44;q11) in a patient with chronic myeloid leukemia. *Leuk Lymphoma.* 2016;57:203-205.
16. Chen L, Wu Y, You Y, Xiao M, Yao Y, Li W. A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient. *Leuk Lymphoma.* 2016;57:2930-2933.
17. Linhartova J, Hovorkova L, Soverini S, Benesova A, Jaruskova M, Klamova H et al. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.(letter). *Mol Cancer* 2015;14:89.
18. Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. *Genes Chromosomes Cancer.* 2012;51:1045-1053.

19. Burmeister T, Gröger D, Kühn A, Hoelzer D, Thiel E, Reinhardt R. Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias. *DNA Repair (Amst)*. 2011;10:1131-1137.
20. Mattarucchi E, Guerini V, Rambaldi A, Campiotti L, Venco A, Pasquali F et al. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. *Genes Chromosomes Cancer*. 2008;47:625-632.
21. Ross DM, Branford S, Seymour JF, Schwarzer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. *Leukemia*. 2010;24:1719-1724.
22. Score J, Calasanz MJ, Ottmann O, Pane F, Yeh RF, Sobrinho-Simoes MA et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. *Leukemia*. 2010;24:1742-1750.
23. Campbell LJ. Deletion of the derivative chromosome 9 in chronic myeloid leukemia. *Methods Mol Med*. 2006;125:107-114.
24. Tchirkov A, Couderc JL, Périssel B, Goumy C, Regnier A, Uhrhammer N et al. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. *Leukemia*. 2006;20:167-168.
25. Wilkinson ME, Charenton C, Nagai K. RNA Splicing by the Spliceosome. *Annu Rev Biochem*. 2020;89:359-388.
26. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouzé P, Brunak S. Splice site prediction in *Arabidopsis thaliana* pre-mRNA by combining local and global sequence information. *Nucleic Acids Res*. 1996;24:3439-3452.
27. Burge C, Karlin S. Prediction of complete gene structures in human genomic DNA. *J Mol Biol*. 1997;268:78-94.
28. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*. 2020;34:966-984.
29. Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN et al. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. *J Cancer Res Clin Oncol*. 2021;147:3081-3089.

Figure Legends

Fig. 1. Time course of the relative *BCR::ABL1* level during twelve months of therapy.

Fig. 2. e8a2 transcript and the identification of breaks on chromosomes 9 and 22.

a: Sequence chromatogram of the *BCR::ABL1* e8a2 transcript.

b: Exon organization of *BCR* and *ABL1* with the location of the 55 bp insert in *ABL1* intron 1b.

c. PCR and sequencing strategy to identify the breaks in *BCR::ABL1*. Upper row: long-range PCR for identification of the 5' break. Lower row: long-range inverse PCR for identification of the 3' break(s). Arrows indicate PCR primer locations and orientations. Gel images show PCR products.

Fig. 3. Hypothetical mechanism leading to the generation of the observed transcript.

a. Break region in *ABL1* intron 1b with the three break positions and formation of the *BCR::ABL1* fusion. The position of repetitive DNA elements and cryptic recombination signal sequences are indicated as arrows or bars.

b. Nucleotide sequence of the cryptic exon with adjacent regions.

Please note that the actual figures and all tables should be uploaded as separate items in their original file format.

Accepted Manuscript

Accepted Manuscript

Accepted Manuscript

Accepted Manuscript